Regulatory
Sep 21, 2026 · 1 min read · 45,974 views
FDA faces questions on 'America First' provisions in latest user fee agreement
N
Noah Patel
Editorial · Sep 21, 2026
Yale and Harvard medical school faculty are questioning whether the FDA and American companies will actually benefit from the US-focused incentives in the next user fee deal. Under
← Previous
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
Next →
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal
